---
title: "Non-HDL-cholesterol and apolipoprotein B compared with…"
description: "Non-HDL-cholesterol and apolipoprotein B may be better indicators of heart disease risk than LDL-cholesterol, especially in certain individuals."
url: "https://magellanlongevity.com/study/d30595507.md"
canonical: "https://magellanlongevity.com/study/d30595507.html"
html: "https://magellanlongevity.com/study/d30595507.html"
type: "study"
study_key: "d30595507"
journal: "Pathology"
year: 2018
pmid: "30595507"
doi: "10.1016/j.pathol.2018.11.006"
citations: 1
updated: 2026-09-02
author: "Gabriel Radu, DO"
author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765."
publisher: "Magellan Longevity"
content_format: "markdown"
---

# Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in cardiovascular disease risk assessment

[Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Non-HDL-cholesterol and apolipoprotein B compared with…

**HTML version:** https://magellanlongevity.com/study/d30595507.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d30595507

## Citation

| Field | Value |
| --- | --- |
| Journal | Pathology |
| Year | 2018 |
| PMID | [30595507](https://pubmed.ncbi.nlm.nih.gov/30595507/) |
| DOI | [10.1016/j.pathol.2018.11.006](https://doi.org/10.1016/j.pathol.2018.11.006) |
| Study key | d30595507 |

## Takeaway

Non-HDL-cholesterol and apolipoprotein B may be better indicators of heart disease risk than LDL-cholesterol, especially in certain individuals.

## The question

What are the measurement, potential role, utility, and current status of non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease (ASCVD) risk assessment?

## Hypothesis

The authors hypothesize that non-HDL-cholesterol and apolipoprotein B (apoB) may be superior to LDL-cholesterol in predicting ASCVD risk, particularly in certain patient populations.

## Methods

This study is a review of existing literature, examining the measurement, potential role, utility, and current status of non-HDL-cholesterol and apoB in comparison to LDL-cholesterol for ASCVD risk assessment.

## Results

LDL-cholesterol is a primary therapeutic target for ASCVD, but its estimation via the Friedewald equation has limitations, and direct measures are not standardized. Non-HDL-cholesterol includes remnant cholesterol and is independent of triglyceride variability, but it is affected by non-specificity bias of direct HDL-cholesterol methods. ApoB measures the number of atherogenic lipoproteins, and its methods are standardized, though it incurs an additional cost. Non-HDL-cholesterol and apoB are more accurate than LDL-cholesterol in individuals with hypertriglyceridemia, in non-fasting samples, and in those with very low LDL-cholesterol. Evidence suggests non-HDL-cholesterol and apoB are superior to LDL-cholesterol in predicting ASCVD risk and are designated as secondary targets in some guidelines.

## Conclusion

Non-HDL-cholesterol and apolipoprotein B offer advantages over LDL-cholesterol in ASCVD risk assessment, particularly in specific patient groups, and accumulating evidence supports their superiority in predicting ASCVD risk.

## Limitations

The review does not present new experimental data or specific quantitative comparisons from a single study, but rather synthesizes existing evidence.

## Verbatim from the abstract

> non-HDL-cholesterol and apoB are superior to LDL-cholesterol in predicting cardiovascular risk

## Where this study is used on Magellan

This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions.

| Compound or device | Evidence grade | Graded pages |
| --- | --- | --- |
| ApoB Home Test Kit | Measurement tool | [ApoB Home Test Kit](https://magellanlongevity.com/p/140.md) |

## Reference

1. **Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in cardiovascular disease risk assessment**
   Pathology 2018 · [PMID 30595507](https://pubmed.ncbi.nlm.nih.gov/30595507/) · [DOI 10.1016/j.pathol.2018.11.006](https://doi.org/10.1016/j.pathol.2018.11.006)

   > non-HDL-cholesterol and apoB are superior to LDL-cholesterol in predicting cardiovascular risk

## Structured data

```json
{"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d30595507.html#page","url":"https://magellanlongevity.com/study/d30595507.html","name":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in cardiovascular disease risk…","description":"Non-HDL-cholesterol and apolipoprotein B may be better indicators of heart disease risk than LDL-cholesterol, especially in certain individuals.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d30595507.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Non-HDL-cholesterol and apolipoprotein B compared with…","item":"https://magellanlongevity.com/study/d30595507.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d30595507.html#study","name":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in cardiovascular disease risk assessment","headline":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in cardiovascular disease risk…","datePublished":"2018","isPartOf":{"@type":"Periodical","name":"Pathology"},"identifier":"PMID:30595507","url":"https://pubmed.ncbi.nlm.nih.gov/30595507/","sameAs":"https://doi.org/10.1016/j.pathol.2018.11.006","abstract":"Non-HDL-cholesterol and apolipoprotein B may be better indicators of heart disease risk than LDL-cholesterol, especially in certain individuals."}]}
```

## Related on Magellan Longevity

- [ApoB Home Test Kit](https://magellanlongevity.com/p/140.md) — product graded on this and related evidence
- [Evidence: Apolipoprotein B particle count](https://magellanlongevity.com/study/s140.md)
- [Physiological Bases for the Superiority of Apolipoprotein B as a Marker of…](https://magellanlongevity.com/study/d36216435.md)
- [Longevity research map](https://magellanlongevity.com/longevity-research-map.html)
- [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md)

## Scope and disclosures

Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication.

Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases.

Reviewed for accuracy by a board-certified physician (DO).